Clinical Trial

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

Study acronym: Cytisinicline
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will randomize 64 non-treatment seeking individuals who smoke cigarettes daily in a double-blind, placebo-controlled laboratory study testing the effects of cytisinicline on the neural substrates of cigarette cue reactivity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-24; most recent amendment 2025-11-25.
Status change: Not Yet Recruiting → Recruiting 2024-11-22
Trial Details
NCT Number NCT06617312
Lead Sponsor University of California, Los Angeles
Conditions Smoking Cessation, Tobacco Use Disorder
Enrollment 64 participants
Start Date 2024-12-05
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-03